Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 22 , ISSUE 12 ( 2018 ) > List of Articles

BRIEF COMMUNICATION

Dilemmas and challenges in treating seronegative autoimmune encephalitis in Indian children

Bandya Sahoo, Mukesh Jain

Keywords : children, clinical clues, seronegative,Autoimmune encephalitis

Citation Information : Sahoo B, Jain M. Dilemmas and challenges in treating seronegative autoimmune encephalitis in Indian children. Indian J Crit Care Med 2018; 22 (12):875-878.

DOI: 10.4103/ijccm.IJCCM_98_18

License: CC BY-ND 3.0

Published Online: 00-12-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Objective: The main objective is to assess the challenges in diagnosis and treatment while managing seronegative cases of autoimmune encephalitis (AIE) in Indian children. Methods: A cohort study of patients with AIE was done where clinical presentations, investigations, management were analyzed and these patients were followed up to assess the evolution of the disease. Results: Nine patients were included in the study. Four patients presented with super-refractory status epilepticus (SRSE). Other presentations were behavioral change, hemiplegia, and autonomic dysfunction. Initial magnetic resonance imaging brain was suggestive of AIE in two patients. Only two were seropositive for cerebrospinal fluid (CSF) autoimmune panel. Five patients responded to the first-line immunotherapy and four required the second-line immunotherapy. Conclusion: The possibility of autoimmune encephalitis should be considered in patients with super-refractory status epilepticus. A large proportion of children with suspected AE may be “seronegative.” A trial of immunotherapy should be given to these children when there is a strong clinical suspicion of autoimmune encephalitis even in the absence of cerebrospinal fluid autoantibodies.


PDF Share
  1. Ahmad SA, Archer HA, Rice CM, Gerhand S, Bradley M, Wilkins A, et al. Seronegative limbic encephalitis: Case report, literature review and proposed treatment algorithm. Pract Neurol 2011;11:355-61.
  2. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California encephalitis project. Clin Infect Dis 2012;54:899-904.
  3. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of encephalitis and differences in their clinical presentations in England: A multicentre, population-based prospective study. Lancet Infect Dis 2010;10:835-44.
  4. Lee SK, Lee ST. The laboratory diagnosis of autoimmune encephalitis. J Epilepsy Res 2016;6:45-50.
  5. Chakrabarty B, Tripathi M, Gulati S, Yoganathan S, Pandit AK, Sinha A, et al. Pediatric anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: Experience of a tertiary care teaching center from North India. J Child Neurol 2014;29:1453-9.
  6. Sudan YS, Vinayan KP, Roy AG, Wagh A, Kannoth S, Patil S, et al. Clinical characteristics and follow-up of South Indian children with autoimmune encephalopathy. Indian J Pediatr 2016;83:1367-73.
  7. Kamble N, Netravathi M, Saini J, Mahadevan A, Yadav R, Nalini A, et al. Clinical and imaging characteristics of 16 patients with autoimmune neuronal synaptic encephalitis. Neurol India 2015;63:687-96.
  8. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11-8.
  9. Ariño H, Armangué T, Petit-Pedrol M, Sabater L, Martinez-Hernandez E, Hara M, et al. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology 2016;87:759-65.
  10. Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: A systematic review. Expert Rev Neurother 2015;15:1391-419.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.